Drugs / EIS-12656
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06525298 | Sep 2024 → Sep 2027 expected | neoplasm | Eisbach Bio GmbH | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EIS-12656 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06525298 ↗ |
| Route | Oral | “EIS-12656 tablets given daily” NCT06525298 ↗ |